Clinical Genomics Continues Progress In Developing Biomarker Portfolio For Colorectal Cancer Testing

< BACK TO BIOTECHNOLOGY starstarstarstarstar   Science - Biotechnology Press Release
29th April 2009, 05:35pm - Views: 476





Science Biotechnology Clinical Genomics Pty Ltd 1 image





Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing


SYDNEY, Apr. 29 /Medianet International-AsiaNet/ --


   To Receive Milestone Payments from Quest Diagnostics


   Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics

Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide

milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based

biomarkers associated with early onset of colorectal cancer. Clinical Genomics was awarded the payments after

successfully achieving key research and development goals. Under terms of a worldwide license agreement, Quest

Diagnostics has exclusive rights to the biomarkers for use in developing a test as an aid in detecting precancerous

and cancerous colorectal tumors in conjunction with other clinical findings. Additional financial terms were not

disclosed.


   Clinical Genomics, in collaboration with Flinders University (South Australia) and the Australian Government's

Commonwealth Scientific and Industrial Research Organization (CSIRO, Australia), has discovered molecular

markers that show promise as aids in detection of both colorectal cancer and precancerous adenomas. 


   "Quest Diagnostics is at the forefront of efforts to develop and offer cancer testing innovations, including gene-

based blood tests and fecal immunochemical tests associated with the detection of colorectal cancer," said

Lawrence LaPointe, CEO of Clinical Genomics. "We are excited that as the world’s leader in cancer diagnostics,

Quest Diagnostics appreciates the potential of our proprietary biomarkers to form the basis for a laboratory test that

one day may aid the detection of early-stage colorectal cancer."


   Colorectal cancer is the second most common cause of cancer related death of both men and women in the

United States and Australia. Colorectal cancer is largely treatable when detected in the early stages. Yet, due to

low screening rates, fewer than 40 percent of cases are caught early [1].


   In 2006, Quest Diagnostics acquired Enterix Inc., manufacturer of the FDA-cleared InSure® fecal

immunochemical test (FIT) for aiding the detection of colorectal cancer based on stool testing. Quest Diagnostics

also made an equity investment in Clinical Genomics, which was formed as a spin off from Enterix’s research and

development. 


[1]American Cancer Society


   About Clinical Genomics


   Clinical Genomics is a Sydney-based biotechnology company formed in 2006 to exploit the patented and patent-

pending gene expression biomarkers of colorectal cancer discovered by its founders and Flinders University in

2001.  Clinical Genomics continues to work closely with Flinders University and CSIRO to advance the

development of products that will improve the detection and management of this serious disease.   Additional




   Contact: (For Clinical Genomics) 

             Lawrence LaPointe, 

             +61 4 0099 5027, 

             larry@clinicalgenomics.com


SOURCE: Clinical Genomics Pty Ltd



To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article